Isotopia Molecular Imaging signed a two-year supply deal to provide Clovis Oncology with lutetium-177 (Lu-177).
Clovis will use Isotopia's Lu-177 in the clinical development of FAP-2286, a fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 consists of two elements: a targeting peptide that binds to FAP and a site that can be used to attach medical radioisotopes, such as Lu-177 for therapeutic use, or gallium-68 (Ga-68) for imaging use.
The company is testing the peptide-targeted radionuclide therapeutic (PTRT) and imaging agent in its LuMIERE phase I/II study in patients with advanced solid cancers.
No other details of the deal were disclosed.
